Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;4(2):FDD77.
doi: 10.4155/fdd-2022-0007. Epub 2022 Jul 19.

CXCR4 as a novel target in immunology: moving away from typical antagonists

Birgit Caspar  1   2   3 , Pietro Cocchiara  4 , Armelle Melet  1   2   3 , Kristof Van Emelen  5 , Annegret Van der Aa  5 , Graeme Milligan  4 , Jean-Philippe Herbeuval  1   2   3
Affiliations
Review

CXCR4 as a novel target in immunology: moving away from typical antagonists

Birgit Caspar et al. Future Drug Discov. 2022 Jun.

Abstract

CXCR4 has been a target of interest in drug discovery for numerous years. However, so far, most if not all studies focused on finding antagonists of CXCR4 function. Recent studies demonstrate that targeting a minor allosteric pocket of CXCR4 induces an immunomodulating effect in immune cells expressing CXCR4, connected to the TLR pathway. Compounds binding in this minor pocket seem to be functionally selective with inverse agonistic properties in selected GPCR signaling pathways (Gi activation), but additional signaling pathways are likely to be involved in the immunomodulating effects. In depth research into these CXCR4-targeted immunomodulators could lead to novel treatment options for (auto)-immune diseases.

Keywords: GPCR; drug design; immunology; small molecule.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Selected small molecule CXCR4 ligands.
Structure of small molecules activating a CXCR4 dependent anti-inflammatory effect (A–E) through binding into the minor pocket of CXCR4. Minor pocket ligands: (A) dopamine, (B) serotonin, (C) histamine, (D) clobenpropit (CB) and (E) IT1t. (F) Structure of small molecule antagonist AMD3100.
Figure 2.
Figure 2.. CXCR4 blocks TLR activation. Activation of TLRs and their down-steam signaling ultimately results in elevated type-I interferons.
This is initiated by pathogens but can also be chronically elevated in auto-immune disease. Novel CXCR4 minor pocket ligands cause inhibition of TLR downstream signaling and subsequent reduction of interferon type-I levels, the exact mode of action remains unclear.
Figure 3.
Figure 3.. Comparison of binding sites at
CXCR 4. Key interaction partners of IT1t are highlighted in red [39], key residues interacting with AMD3100 are highlighted in blue [41,57] and shared residues in purple. (A) top view of the receptor and (B) snake plot of CXCR4. CXCR4 plots adapted from GPCRdb [58].
Figure 4.
Figure 4.. Hypothetical signalling of IT1t at CXCR4.
IT1t has been published to inhibit Gi2 signaling. Hypothetical signaling promoted further downstream at CXCR4 by IT1t and potentially other minor pocket ligands include the cAMP, PI3K/Akt and MAPK pathway; several of these pathways have been shown to regulate inflammation.
See this image and copyright information in PMC

References

    1. Arimont M, Sun SL, Leurs R, Smit M, de Esch IJP, de Graaf C. Structural analysis of chemokine receptor–ligand interactions. J. Med. Chem. 60(12), 4735–4779 (2017). - PMC - PubMed
    1. Bachelerie F, Ben-Baruch A, Burkhardt AM et al. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66(1), 1–79 (2013). - PMC - PubMed
    1. Zlotnik A, Yoshie O, Nomiyama H. The chemokine and chemokine receptor superfamilies and their molecular evolution. Genome Biol. 7(12), 243.1–243.11 (2006). - PMC - PubMed
    1. Bernhagen J, Krohn R, Lue H et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13(5), 587–596 (2007). - PubMed
    1. Britton C, Poznansky MC, Reeves P et al. Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: implications for therapeutic interventions in cancer and immune-mediated diseases. FASEB J. 35(4), 1–20 (2021). - PubMed

LinkOut - more resources